BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 168 produtos para "BTK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Fórmula:C25H23ClN4O4Pureza:98.68% - 99.63%Cor e Forma:SolidPeso molecular:478.93AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Fórmula:C33H31FN6O3Pureza:≥95%Cor e Forma:SolidPeso molecular:578.64IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Fórmula:C22H22N6OPureza:99.88% - 99.88%Cor e Forma:Yellow SolidPeso molecular:386.45Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Fórmula:C25H23ClN6O3Pureza:99.27% - 99.95%Cor e Forma:White SolidPeso molecular:490.94MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Fórmula:C41H41N9O8Pureza:95.93% - 97.60%Cor e Forma:SolidPeso molecular:787.82Ref: TM-T16157
1mg92,00€5mg177,00€1mL*10mM (DMSO)231,00€10mg269,00€25mg510,00€50mg692,00€100mg888,00€200mg1.251,00€Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Cor e Forma:White SolidPeso molecular:665.76Ref: TM-T12542
1mg94,00€5mg222,00€1mL*10mM (DMSO)325,00€10mg356,00€25mg620,00€50mg893,00€100mg1.251,00€500mg2.502,00€Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Fórmula:C24H25N5O3Pureza:99.94%Cor e Forma:SolidPeso molecular:431.49Ref: TM-T10629
1mg34,00€2mg49,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg98,00€25mg215,00€50mg356,00€100mg434,00€Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.Fórmula:C26H23N7O2Pureza:99.20%Cor e Forma:SolidPeso molecular:465.51Ref: TM-T67881
200mgA consultar1mg80,00€5mg168,00€1mL*10mM (DMSO)178,00€10mg238,00€25mg379,00€50mg513,00€100mg707,00€Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Fórmula:C26H25N3O3Pureza:97.77% - 99.54%Cor e Forma:SolidPeso molecular:427.49Ref: TM-T12317
1mg86,00€5mg177,00€1mL*10mM (DMSO)205,00€10mg299,00€25mg492,00€50mg682,00€100mg897,00€500mg1.791,00€SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Fórmula:C41H45ClN8O7Pureza:98%Cor e Forma:SolidPeso molecular:797.3TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Cor e Forma:Odour SolidCNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Fórmula:C48H68N10O9SPureza:98%Cor e Forma:SolidPeso molecular:961.18BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Fórmula:C23H23ClFN7O2Cor e Forma:SolidPeso molecular:483.93DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Fórmula:C55H62N10O8Cor e Forma:SolidPeso molecular:991.163NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Fórmula:C43H51N11O6Cor e Forma:SolidPeso molecular:817.94BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Cor e Forma:Odour SolidGBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Fórmula:C44H47N9O6Pureza:98%Cor e Forma:SolidPeso molecular:797.9BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Fórmula:C25H24F3N7O3Cor e Forma:SolidPeso molecular:527.508PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Fórmula:C43H43N9O4Cor e Forma:SolidPeso molecular:749.86Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Fórmula:C8H6BrN3SPureza:99.94%Cor e Forma:White SolidPeso molecular:256.12
